OTCMKTS:ISCO - International Stem Cell Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.56 -0.04 (-2.50 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$1.60
Today's Range$1.56 - $1.56
52-Week Range$1.08 - $2.05
Volume200 shs
Average Volume6,789 shs
Market Capitalization$9.91 million
P/E Ratio-1.07
Dividend YieldN/A
Beta-0.39
International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

Receive ISCO News and Ratings via Email

Sign-up to receive the latest news and ratings for ISCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ISCO
CUSIPN/A
Phone760-940-6383

Debt

Debt-to-Equity RatioN/A
Current Ratio0.59
Quick Ratio0.35

Price-To-Earnings

Trailing P/E Ratio-1.07
Forward P/E Ratio-1.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.46 million
Price / Sales1.30
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book4.59

Profitability

EPS (Most Recent Fiscal Year)($1.46)
Net Income$-6,060,000.00
Net Margins-47.19%
Return on Equity-300.39%
Return on Assets-51.07%

Miscellaneous

Employees40
Outstanding Shares6,200,000
Market Cap$9.91

The Truth About Cryptocurrencies

International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions

What is International Stem Cell's stock symbol?

International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."

How were International Stem Cell's earnings last quarter?

International Stem Cell Corp (OTCMKTS:ISCO) issued its quarterly earnings results on Tuesday, May, 22nd. The biotechnology company reported ($0.14) earnings per share for the quarter. The biotechnology company had revenue of $2.63 million for the quarter. International Stem Cell had a negative return on equity of 300.39% and a negative net margin of 47.19%. View International Stem Cell's Earnings History.

When is International Stem Cell's next earnings date?

International Stem Cell is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for International Stem Cell.

What is the consensus analysts' recommendation for International Stem Cell?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for International Stem Cell in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of International Stem Cell's key competitors?

Who are International Stem Cell's key executives?

International Stem Cell's management team includes the folowing people:
  • Prof. Andrey Semechkin, Co-Chairman & CEO (Age 58)
  • Dr. Russell Kern, Exec. VP, Chief Scientific Officer & Director (Age 32)
  • Mr. Kenneth C. Aldrich, Co-Founder and Chairman Emeritus (Age 79)
  • Ms. Sophia Garnette J.D., VP of Legal Affairs & Operations and Sec. (Age 34)
  • Mr. Francisco Bustamante, Pres of Lifeline Cell Technology LLC

Has International Stem Cell been receiving favorable news coverage?

News articles about ISCO stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. International Stem Cell earned a media sentiment score of 0.14 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of International Stem Cell?

Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is International Stem Cell's stock price today?

One share of ISCO stock can currently be purchased for approximately $1.56.

How big of a company is International Stem Cell?

International Stem Cell has a market capitalization of $9.91 million and generates $7.46 million in revenue each year. The biotechnology company earns $-6,060,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. International Stem Cell employs 40 workers across the globe.

How can I contact International Stem Cell?

International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected]


MarketBeat Community Rating for International Stem Cell (OTCMKTS ISCO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote "Outperform" if you believe ISCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.